Peng Wanhong, Wang Si, Yu Minglan, Wang Tingting, He Rongfang, Liu Dongmei, Chen Dechao, Liang Xuemei, Liu Kezhi, Xiang Bo
Department of Psychiatry, Laboratory of Neurological Diseases and Brain Function, Medical Laboratory Center, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People's Republic of China.
The Fourth People's Hospital of Chengdu, Chengdu, Sichuan Province, People's Republic of China.
Neuropsychiatr Dis Treat. 2023 Aug 2;19:1763-1770. doi: 10.2147/NDT.S411575. eCollection 2023.
Although electroconvulsive therapy (ECT) has been employed as an effective treatment strategy and to improve mental symptoms in schizophrenia (SCZ), its action mechanisms remain unclear. Our previous study found that some genes and biological pathways were closely related to ECT through genetic technology analysis, such as LTP pathway and . This study combined with healthy controls and symptomatology analysis to further explore the changes of expression of EP300 protein in treatment and related symptoms of SCZ.
One hundred and one patients with SCZ and 45 healthy controls (HCs) were enrolled in this study. Patients with SCZ received acute courses of 6 times bilateral ECT. The peripheral blood of patients with SCZ (BECT: before ECT; AECT: after ECT) and the HCs was collected to calculate the changes of expression level of EP300 protein by enzyme-linked immunosorbent assay. The Positive and Negative Symptoms Scale (PANSS) was used to evaluate the severity of symptoms of SCZ patients and the efficiency of the ECT.
There was a statistical difference of EP300 protein expression in patients with SCZ (BECT and AECT) (F = 114.5, < 0.05). ECT reduced plasma expression level of EP300 protein in patients with SCZ, which was not statistically different from that in HCs (t = 4.47, = 0.20). The change of the expression level of EP300 protein in patients with SCZ (BECT and AECT) has a positive correlation with reduction rate of positive symptoms (r = 0.228, < 0.05) and disturbance of thought (r = 0.219, < 0.05).
Our study suggests that the expression level of EP300 protein has a significant change in patients with SCZ treating with ECT, and EP300 may have some connections with positive symptoms and disturbance thought of patients with SCZ.
尽管电休克治疗（ECT）已被用作一种有效的治疗策略来改善精神分裂症（SCZ）的精神症状，但其作用机制仍不清楚。我们之前的研究通过基因技术分析发现一些基因和生物学途径与ECT密切相关，如长时程增强（LTP）途径等。本研究结合健康对照和症状学分析，进一步探讨SCZ治疗过程中EP300蛋白表达变化及其与相关症状的关系。
本研究纳入101例SCZ患者和45名健康对照（HCs）。SCZ患者接受6次双侧ECT急性疗程。采集SCZ患者（ECT前：BECT；ECT后：AECT）和HCs的外周血，采用酶联免疫吸附测定法计算EP300蛋白表达水平的变化。采用阳性和阴性症状量表（PANSS）评估SCZ患者症状严重程度及ECT疗效。
SCZ患者（BECT和AECT）的EP300蛋白表达存在统计学差异（F = 114.5，P < 0.05）。ECT降低了SCZ患者血浆中EP300蛋白表达水平，与HCs相比无统计学差异（t = 4.47，P = 0.20）。SCZ患者（BECT和AECT）的EP300蛋白表达水平变化与阳性症状缓解率（r = 0.228，P < 0.05）及思维障碍（r = 0.219，P < 0.05）呈正相关。
我们的研究表明，接受ECT治疗的SCZ患者EP300蛋白表达水平有显著变化，且EP300可能与SCZ患者的阳性症状及思维障碍存在一定关联。
